

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope	
Iron Agents	MP-RX-FP-44-23	☒ MMM MA	☒ MMM Multihealth
Service Category			
☐ Anesthesia ☐ Surgery ☐ Radiology Procedures ☐ Pathology and Laboratory Procedures ☐ Medicine Services and Procedures ☐ Evaluation and Management Services ☐ DME/Prosthetics or Supplies ☒ Part B Drugs			
Service Description			
This document addresses the use of Ferumoxytol (Feraheme), Ferric carboxymaltose (Injectafer), Sodium ferric gluconate/sucrose complex (Ferrlecit), Iron dextran (Infed), Ferric carboxymaltose (Injectafer), Ferric derisomaltose (Monoferric), Ferric pyrophosphate citrate (Triferic, Triferic AVNU), Iron sucrose (Venofer), a drug approved by the Food and Drug Administration (FDA) for the treatment of iron deficiency anemia (IDA).			
Background Information			
This document addresses the use of injectable agents for the treatment of iron deficiency anemia (IDA). Agents addressed in this document include: • Feraheme (ferumoxytol) • Ferrlecit (sodium ferric gluconate/sucrose complex) • Infed (iron dextran) • Injectafer (ferric carboxymaltose) • Monoferric (ferric derisomaltose) • Triferic, Triferic AVNU (ferric pyrophosphate citrate) • Venofer (iron sucrose) Iron is a mineral in the body that is an essential component for blood production, enabling them to carry oxygen throughout the body. The majority of body iron are found in circulating red blood cells called hemoglobin, while the remaining is stored as ferritin or bound to myoglobin in muscle cells. Individuals with iron deficiency anemia may have mild to severe symptoms, ranging from fatigue, shortness of breath, and chest pain to heart failure and developmental delays in children (NHLBI 2019). The causes of iron deficiency anemia are numerous, including gastrointestinal bleeding or other blood loss, chronic kidney disease, celiac disease, multiple blood donations, and cancer or chemotherapy-related etiologies. Diagnosis of IDA is typically confirmed by evaluating levels of serum ferritin, transferrin saturation (TSAT), absence of stainable iron in the bone marrow, or resolution of anemia upon iron administration (Auerbach 2020). While the 2012 Kidney Disease Improving Global Outcomes (KDIGO) guidelines for anemia in chronic kidney disease do not provide any guidance on preference of available IV iron agents over another, they do suggest that a trial oral iron for 1 to 3 months can be appropriate for individuals with IDA prior to initiating IV iron. The National Comprehensive Cancer Network (NCCN) guidelines for Hematopoietic Growth Factors provides a category 2A			

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Iron Agents	MP-RX-FP-44-23	☒ MMM MA ☒ MMM Multihealth
recommendation for use of Feraheme, Ferrlecit, Infed (IV only; IM not recommended), Injectafer, Venofer, and Monoferic for the management of cancer- and chemotherapy-induced anemia. NCCN also suggests that a trial of oral iron for at least 4 weeks can be appropriate prior to initiating IV iron. Both Feraheme and Infed have black box warnings for fatal and serious hypersensitivity reactions including anaphylaxis, and as such, the administration of which should only occur when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions. Applicable Codes The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Guidelines may apply.		
HCPCS	Description	
J1443	Injection, ferric pyrophosphate citrate solution, 0.1 mg of iron [Triferic]	
J1445	Injection, ferric pyrophosphate citrate solution (Triferic AVNU), 0.1 mg of iron	
J1437	Injection, ferric derisomaltose, 10 mg [Monoferic]	
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for non-ESRD on dialysis) [Feraheme]	
J2916	Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg [Ferrlecit]	
J1750	Injection, iron dextran, 50 mg [Infed]	
J1756	Injection, iron sucrose, 1 mg [Venofer]	
J1439	Injection, ferric carboxymaltose, 1 mg [Injectafer]	
ICD-10	Description	
D50.0-D50.9	Iron deficiency anemia	
D63.0-D63.8	Anemia in chronic diseases classified elsewhere	
D64.81	Anemia due to antineoplastic chemotherapy	
E61.1	Iron deficiency anemia	
K50.00-K50.919	Crohn's disease [regional enteritis]	
K90.0-K90.9	Celiac disease	
N18.1-N18.5	Chronic kidney disease, stages I-V	
O99.011	Anemia complicating pregnancy, first trimester	
O99.012	Anemia complicating pregnancy, second trimester	
O99.013	Anemia complicating pregnancy, third trimester	
O99.019	Anemia complicating pregnancy, unspecified trimester	

Medical Necessity Guidelines

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

Feraheme (ferumoxytol), Ferrlecit (sodium ferric gluconate/sucrose complex), Infed (iron dextran), Injectafer (ferric carboxymaltose), Venofer (iron sucrose)

A. Criteria For Initial Approval

- I. Individual has a diagnosis of chronic kidney disease (CKD); **AND**
 - A. Individual is dialysis dependent; **AND**
 - B. Individual has iron deficiency anemia (IDA);
- OR**
- II. Individual has a diagnosis of iron deficiency anemia (IDA) or iron deficiency; **AND**
- III. Individual is non-dialysis dependent; **AND**
- IV. Diagnosis is confirmed by one of the following:
 - A. For IDA associated with CKD or inflammatory conditions (for example, inflammatory bowel disease [IBD], heart failure), individual meets one of the following within the last four (4) weeks (De Franceschi 2017):
 1. Serum ferritin levels less than 100 ng/mL; **OR**
 2. TSAT levels less than 20%; **OR**
 3. Serum ferritin is less than or equal to 500 ng/mL and TSAT is less than or equal to 30% (KDIGO 2012); **OR**
 4. Bone marrow demonstrates inadequate iron stores; **OR**
 5. Hemoglobin (HGB) less than 13 g/dl (less than 130 g/l) in males or less than 12 g/dl (less than 120 g/l) in females and TSAT 30% or less and ferritin 500ng/ml or less (500 µg/l or less) (Ko 2020); **OR**
 - B. For IDA associated with cancer/chemotherapy or non-inflammatory conditions (for example, blood loss, malabsorption, malnutrition), individual meets one of the following within the last four (4) weeks (NCCN 2021, De Franceschi 2017):
 1. Serum ferritin levels less than 30 ng/mL; **OR**
 2. TSAT levels less than 20%; **OR**
 3. Bone marrow demonstrates inadequate iron stores; **AND**
- V. Individual has had a four (4) week trial of and inadequate response, or intolerance to oral iron supplementation (NCCN 2020, KDIGO 2012); **OR**
- VI. Individual is unable to use oral iron supplementation for one of the following reasons:
 - A. Malabsorption conditions; **OR**
 - B. Gastric Surgery (DeFlipp 2013);
- OR**
- VII. Individual has iron deficiency anemia in pregnancy; **AND**
- VIII. Diagnosis is confirmed by one of the following:

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Iron Agents	MP-RX-FP-44-23	☒ MMM MA ☒ MMM Multihealth
A. Serum ferritin levels less than 30 ng/mL; OR B. TSAT levels less than 20%; OR C. Bone marrow demonstrates inadequate iron stores; AND IX. Individual is past 14 weeks of pregnancy and has had a four (4) week trial of and inadequate response, or intolerance to oral iron supplementation (Muñoz 2017); OR X. Individual is past 14 weeks of pregnancy and individual is unable to use oral iron supplementation due to malabsorptive conditions or gastric surgery (Muñoz 2017, DeFlipp 2013); OR XI. Individual is past 14 weeks of pregnancy and diagnosed with severe iron deficiency anemia, defined as Hemoglobin (HGB) less than 8 g/dL; OR XII. Individual is past 34 weeks of pregnancy OR XIII. ONLY for INFED (Iron dextran): Individual is diagnosed with iron deficiency due to blood loss; AND XIV. Diagnosis is confirmed by one of the following: A. Serum ferritin levels less than 100 ng/mL; OR B. TSAT levels less than 20%; OR C. Serum ferritin is less than or equal to 500 ng/mL and TSAT is less than or equal to 30% (KDIGO 2012); OR D. Bone marrow demonstrates inadequate iron stores. OR XV. ONLY for Injectafer (ferric carboxymaltose): Individual is diagnosed with iron deficiency in adult patients with heart failure with New York Heart Association class II/III; AND XVI. Individual is using to improve exercise capacity; AND XVII. Diagnosis is confirmed by one of the following (Heidenreich 2022): A. Serum ferritin levels less than 100 µg/L; OR B. TSAT levels less than 20% and ferritin level 100 to 300 µg/L. B. Criteria For Continuation of Therapy: N/A C. Authorization Duration (dialysis-dependent use excluded): 6 months D. Conditions Not Covered <i>Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):</i> Feraheme (ferumoxytol), Ferrlecit (sodium ferric gluconate/sucrose complex), Infed (iron dextran), Injectafer (ferric carboxymaltose), or Venofer (iron sucrose) may not be approved when the above criteria are not met and for all other indications.		

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Iron Agents	MP-RX-FP-44-23	☒ MMM MA ☒ MMM Multihealth
Monoferic (ferric derisomaltose)		
A. Criteria For Initial Approval		
I. Individual has a diagnosis of iron deficiency anemia (IDA) or iron deficiency; AND		
II. Individual is non-dialysis dependent; AND		
III. Diagnosis is confirmed by one of the following: A. For IDA associated with CKD or inflammatory conditions (for example, inflammatory bowel disease [IBD], heart failure), individual meets one of the following within the last four (4) weeks (De Franceschi 2017): 1. Serum ferritin levels less than 100 ng/mL; OR 2. TSAT levels less than 20%; OR 3. Serum ferritin is less than or equal to 500 ng/mL and TSAT is less than or equal to 30% (KDIGO 2012); OR 4. Bone marrow demonstrates inadequate iron stores; OR 5. Hemoglobin (HGB) less than 13 g/dl (less than 130 g/l) in males or less than 12 g/dl (less than 120 g/l) in females and TSAT 30% or less and ferritin 500ng/ml or less (500 µg/l or less) (Ko 2020); OR B. For IDA associated with cancer/chemotherapy or non-inflammatory conditions (for example, blood loss, malabsorption, malnutrition), individual meets one of the following within the last four (4) weeks (NCCN 2021, De Franceschi 2017): 1. Serum ferritin levels less than 30 ng/mL; OR 2. TSAT levels less than 20%; OR 3. Bone marrow demonstrates inadequate iron stores; AND		
IV. Individual has had a four (4) week trial of and inadequate response, or intolerance to oral iron supplementation (NCCN 2020, KDIGO 2012); OR		
V. Individual is unable to use oral iron supplementation for one of the following reasons: A. Malabsorption conditions; OR B. Gastric Surgery (DeFlipp 2013);		
C. Criteria For Continuation of Therapy: N/A		
D. Authorization Duration: 6 months		
E. Conditions Not Covered		
<i>Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):</i>		
I. Individual has hemodialysis dependent chronic kidney disease (CKD); OR		
II. When the above criteria are not met and for all other indications.		

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope	
Iron Agents	MP-RX-FP-44-23	☒ MMM MA	☒ MMM Multihealth

Triferic/Triferic AVNU (ferric pyrophosphate citrate)

A. Prescriber Specialties: N/A

B. Criteria For Initial Approval

- i. Individual has a diagnosis of chronic kidney disease (CKD); **AND**
- ii. Individual is hemodialysis dependent; **AND**
- iii. Individual has iron deficiency anemia (IDA).

C. Criteria For Continuation of Therapy: N/A

D. Authorization Duration: 6 months

E. Conditions Not Covered
Any other use is considered experimental, investigational, or unproven, including the following (this list may not be all inclusive):

- I. Peritoneal dialysis; **OR**
- II. When the above criteria are not met and for all other indications.

Summary of FDA-approved and NCCN 2A recommended indications for agents for Iron Deficiency Anemia (IDA):

Agent	Route	Oral iron intolerant or unresponsive IDA	CKD	Dialysis-dependent CKD only	NCCN
Feraheme (ferumoxytol)	IV	X	X		X
Ferrlecit (sodium ferric gluconate/sucrose complex)	IV			X*	X
Infed (iron dextran)	IV, IM	X*			X (IV only)
Injectafer (ferric carboxymaltose)	IV	X	X		X
Monoferic (ferric carboxymaltose)	IV	X	X		X
Triferic, Triferic AVNU (ferric pyrophosphate citrate)	IV			X	
Venofer (iron sucrose)	IV		X*		X

*Includes FDA-approved pediatric indication.

Note: When an IDA agent is deemed approvable based on the clinical criteria above, the benefit plan may have additional criteria requiring the use of a preferred agent or agents.

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Iron Agents	MP-RX-FP-44-23	☒ MMM MA ☒ MMM Multihealth

Limits or Restrictions

A. Therapeutic Alternatives

The list below includes preferred alternative therapies recommended in the approval criteria and may be subject to prior authorization.

N/A

B. Quantity Limitations

Iron Deficiency Anemia Agents Quantity Limits

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines. The chart below includes dosing recommendations as per the FDA-approved prescribing information.

Drug	Limit
Feraheme (ferumoxitol) 510 mg/17 mL vial*	2 vials per 6 days‡
Ferrlecit (sodium ferric gluconate/sucrose complex) 62.5 mg/5 mL vial*	16 vials per 8 weeksΔ
Injectafer (ferric carboxymaltose) 750 mg/15 mL vial*	2 vials per 14 days‡
Injectafer (ferric carboxymaltose) 100mg/2ml vial*	7 vials per 7 days
Injectafer (ferric carboxymaltose) 1000 mg/20 mL vial*	1 vial per 7 days
Monoferic (ferric derisomaltose) 100 mg/mL vial	4 vials per day
Monoferic (ferric derisomaltose) 500 mg/5 mL vial	1 vial per day
Monoferic (ferric derisomaltose) 1000 mg/10 mL vial	1 vial per day‡
Venofer (iron sucrose) 50 mg/2.5 mL vial*	6 vials per 12 weeks
Venofer (iron sucrose) 100 mg/5 mL vial*	3 vials per 12 weeks
Venofer (iron sucrose) 200 mg/10 mL vial*	5 vials per 14 days‡
Override Criteria	
*Use in dialysis-dependent individuals excluded from quantity limits.	

‡ Limit represents FDA-approved maximum dose recommendations per course of therapy (excluding dialysis-dependent diagnosis).

ΔLimit according to NCCN guidelines for hematopoietic growth factors (v4.2021).

Reference Information

1. Achebe MM, Gafter-Gvili A. How I treat anemia in pregnancy: iron, cobalamin, and folate. *Blood*. 2017;129(8):940-949. doi:10.1182/blood-2016-08-672246
2. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. “Anemia in Pregnancy: ACOG Practice Bulletin, Number 233.” *Obstetrics and gynecology* vol. 138,2 (2021): e55-e64. doi:10.1097/AOG.0000000000004477
3. Auerbach M. Causes and diagnosis of iron deficiency and iron deficiency anemia in adults. Last updated June 2021. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. Accessed: June 27, 2022.
4. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
5. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 27, 2022.
6. De Franceschi L, Iolascon A, Taher A, Cappellini MD. Clinical management of iron deficiency anemia in adults: Systemic review on advances in diagnosis and treatment. *Eur J Intern Med*. 2017;42:16–23.
7. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
8. Ferritin in Pediatrics. American Association for Clinical Chemistry (AACC Academy). 2022. Available at: <https://www.aacc.org/advocacy-and-outreach/optimal-testing-guide-to-lab-test-utilization/a-f/ferritin-in-pediatrics>. Accessed on June 27, 2022.
9. Haymond, Shannon. American Association for Clinical Chemistry (AACC Academy). 2022. Available at: <https://www.aacc.org/science-and-research/clinical-chemistry-trainee-council/trainee-council-in-english/pearls-of-laboratorymedicine/2015/iron-deficiency-anemia>. Accessed on: June 27, 2022.
10. Iron-Deficiency Anemia. National Heart, Lung, and Blood Institute (NHLBI). 2022. Available at <https://www.nhlbi.nih.gov/healthtopics/iron-deficiency-anemia>. Accessed on: June 27, 2022.
11. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. *Kidney Inter*. 2012; Suppl 2: 279–335. Available from: https://www.kidney.org/professionals/guidelines/guidelines_commentaries/anemia. Accessed on: June 27, 2022.
12. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.
13. Muñoz, M et al. “Patient blood management in obstetrics: management of anaemia and haematinic deficiencies in pregnancy and in the post-partum period: NATA consensus statement.” *Transfusion medicine (Oxford, England)* vol. 28,1 (2018): 22-39. doi:10.1111/tme.12443
14. NCCN Clinical Practice Guidelines in Oncology™. © 2021 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on June 27, 2022. a. Hematopoietic Growth Factors. V1.2022. Revised December 22, 2021.
15. Pavord, Sue et al. “UK guidelines on the management of iron deficiency in pregnancy.” *British journal of haematology* vol. 188,6 (2020): 819-830. doi:10.1111/bjh.16221
16. Peyrin-Biroulet L, Williet N, Cacoub P. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. *Am J Clin Nutr*. 2015;102(6):1585–1594.
17. Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. *Am Fam Physician*. 2013;87(2):98-104.

Medical Policy

Healthcare Services Department

Policy Name	Policy Number	Scope
Iron Agents	MP-RX-FP-44-23	☒ MMM MA ☒ MMM Multihealth
Federal and state laws or requirements, contract language, and Plan utilization management programs or polices may take precedence over the application of this clinical criteria. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan. © CPT Only – American Medical Association		

Policy History

Revision Type	Summary of Changes	P&T Approval Date	MPCC Approval Date
Annual Review 6/16/2025	Minimal changes: word formatting. No coding changes.	7/17/2025	8/8/2025
Select Review 06/06/2025	Removal of step therapy requirement.	N/A	N/A
Annual Review 07/15/2024	Add hemoglobin in diagnosis, edit oral iron requirement, update Infed criteria to include iron deficiency from blood loss, Add Injectafer criteria related to heart failure, increase approval length to 6 monyhs; Add iron deficiency clarification, add oral iron exception requirements to anemia in pregnancy, clarify blood loss iron deficiency for Infed; Coding Reviewed: Add ICD-10-CM E61.1	2/24/2025	3/6/2025
Policy Inception 08/18/2023	Elevance Health's Medical Policy adoption.	N/A	11/30/2023